Signs and symptoms of overdose
The toxic dose of misoprostol in humans has not been determined. Clinical signs that may indicate an overdose are sedation, tremor, convulsions, dyspnea, abdominal pain, diarrhoea, fever, palpitations, hypotension, or bradycardia.
Treatment of overdose
Because misoprostol is metabolized like a fatty acid, it is unlikely that dialysis would be appropriate treatment for overdosage. In cases of overdose, standard supportive measures should be adopted as required.
In clinical trials patients have tolerated 1200 micrograms daily for three months without significant adverse effects.
Misoprostol is contraindicated:
- In women who are pregnant, or in whom pregnancy has not been excluded, or who are planning a pregnancy as misoprostol increases uterine tone and contractions in pregnancy which may cause partial or complete expulsion of the products of conception. Use in pregnancy has been associated with birth defects.
- In patients with a known hypersensitivity to misoprostol or to any other component of the product, or to other prostaglandins.
Not applicable.
The Adverse reaction terms were then categorised utilising the incidence rate as follows:
| Very Common: > 1/10 (>10%) |
| Common: > 1/100 and < 1/10, (>1% and <10%) |
| Uncommon: > 1/1000 and < 1/100, (>0.1% and <1%) |
| Rare: > 1/10,000 and < 1/1000, (>0.01% and <0.1%) |
| Very Rare: < 1/10,000, (<0.01%) |
| Not Known |
| Immune System Disorder Not Known | Anaphylactic reaction |
| Nervous System Disorders Common | Dizziness, headache |
| Gastrointestinal Disorders Very common Common | Diarrhoea* Abdominal pain*, constipation, dyspepsia, flatulence, nausea, vomiting |
| Skin and Subcutaneous Tissue Disorders Very Common | Rash |
| Pregnancy, puerperium, and perinatal conditions Not Known | Amniotic fluid embolism, abnormal uterine contractions, foetal death, incomplete abortion, premature birth, retained placenta, uterine rupture, uterine perforation |
| Reproductive System and Breast Disorders Uncommon Rare Not Known | Vaginal haemorrhage (including postmenopausal bleeding), intermenstrual bleeding, menstrual disorder, uterine cramping Menorrhagia, dysmenorrhoea Uterine haemorrhage |
| Congenital, Familial and Genetic Disorders Not Known | Birth defects |
| General Disorders and Administration Site Conditions Not Known Uncommon | Chills Pyrexia |
* Diarrhoea and abdominal pain were dose-related, usually developed early in the course of therapy, and were typically self-limiting. Rare instances of profound diarrhoea leading to severe dehydration has been reported.
Diarrhoea can be minimised by using single doses not exceeding 200 micrograms with food and by avoiding the use of predominantly magnesium containing antacids when an antacid is required.
The pattern of adverse events associated with Mirolut is similar when an NSAID is given concomitantly.
Clinical trials:
In clinical trials, over 15,000 patients and subjects received at least one dose of misoprostol. Adverse reactions involved primarily the gastrointestinal system.
Diarrhoea and abdominal pain were dose-related, usually developed early in the course of therapy, and were typically self-limiting. Rare instances of profound diarrhoea leading to severe dehydration have been reported.
The profile for adverse reactions with >1% incidence was similar for subacute (four to twelve weeks duration) and long- term (up to one year) clinical trials.
The safety of long-term (greater than 12 weeks) administration of misoprostol has been demonstrated in several studies in which patients were treated continuously for up to one year. This includes no adverse or unusual change in the morphology of gastric mucosa, as determined by gastric biopsy.
Special populations:
There were no significant differences in the safety profile of misoprostol in patients who were 65 years of age or older, compared with younger patients.
The use of misoprostol in children has not been evaluated.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.
In single and repeat-dose studies in dogs, rats and mice at multiples of the human dose, toxicological findings were consistent with the known pharmacological effects of the E-type prostaglandins, the main symptoms being diarrhoea, vomiting, mydriasis, tremors and hyperpyrexia. Gastric mucosal hyperplasia was also observed in the mouse, rat and the dog. In the rat and the dog the hyperplasia was reversible on discontinuation of misoprostol following one year of dosing. Histological examination of gastric biopsies in humans has shown no adverse tissue response after up to one year's treatment. In studies of fertility, teratogenicity and peri/post-natal toxicity in rats and rabbits there were no major findings. A decrease in implantations and some pup growth retardation was observed at doses greater than 100 times the human dose. It was concluded that misoprostol does not significantly affect fertility, is not teratogenic or embryotoxic and does not affect rat pups in the peri/post-natal period.
Misoprostol was negative in a battery of 6 in vitro assays and one in vivo test to assess mutagenic potential. In carcinogenicity studies in the rat and mouse it was concluded that there was no risk of carcinogenic hazard.
Mirolut is indicated for the healing of duodenal ulcer and gastric ulcer including those induced by nonsteroidal anti-inflammatory drugs (NSAID) in arthritic patients at risk, whilst continuing their NSAID therapy. In addition, Mirolut can be used for the prophylaxis of NSAID-induced ulcers.
Pharmacotherapeutic group: prostaglandins, ATC code: A02BB01.
Mirolut is an analogue of naturally occurring prostaglandin E1 which promotes peptic ulcer healing and symptomatic relief.
Mechanism of action
Mirolut protects the gastroduodenal mucosa by inhibiting basal, stimulated and nocturnal acid secretion and by reducing the volume of gastric secretions, the proteolytic activity of the gastric fluid, and increasing bicarbonate and mucus secretion.
Mirolut is rapidly absorbed following oral administration, with peak plasma levels of the active metabolite (misoprostol acid) occurring after about 30 minutes. The plasma elimination half-life of misoprostol acid is 20-40 minutes. No accumulation of misoprostol acid in plasma occurs after repeated dosing of 400 micrograms twice daily.
Women of childbearing potential should not be started on misoprostol until pregnancy is excluded, and should be fully counselled on the importance of adequate contraception while undergoing treatment. If pregnancy is suspected, use of the product should be discontinued.
In such patients it is advised that Mirolut should only be used if the patient:
- takes effective contraceptive measures
- has been advised of the risks of taking Mirolut if pregnant
Gastrointestinal bleeding, ulceration, and perforation have occurred in NSAID-treated patients receiving misoprostol. Physicians and patients should remain alert for ulceration, even in the absence of gastrointestinal symptoms, and, where appropriate, endoscopy and biopsy should be carried out before use to ensure that malignant disease is absent in the upper gastrointestinal tract. These investigations and any others considered necessary by the clinician should be repeated at appropriate intervals for follow-up purposes.
Symptomatic responses to misoprostol do not preclude the presence of gastric malignancy.
Misoprostol should be used with caution in patients with conditions that predispose them to diarrhoea, such as inflammatory bowel disease. To minimise the risk of diarrhoea, misoprostol should be taken with food, and magnesium-containing antacids should be avoided.
Misoprostol should be used with caution in patients in whom dehydration would be dangerous. These patients should be monitored carefully.
The results of clinical studies indicate that Mirolut does not produce hypotension at dosages effective in promoting the healing of gastric and duodenal ulcers. Nevertheless, Mirolut should be used with caution in the presence of disease states where hypotension might precipitate severe complications, e.g. cerebrovascular disease, coronary artery disease or severe peripheral vascular disease including hypertension.
There is no evidence that Mirolut has adverse effects on glucose metabolism in human volunteers or patients with diabetes mellitus.
Mirolut can cause dizziness. Patients should be cautioned about operating machinery and driving.
Posology
Adults
Healing of duodenal ulcer, gastric ulcer and NSAID-induced peptic ulcer: 800 micrograms daily in two or four divided doses taken with breakfast and / or each main meal and at bedtime.
Treatment should be given initially for at least 4 weeks even if symptomatic relief has been achieved sooner. In most patients ulcers will be healed in 4 weeks but treatment may be continued for up to 8 weeks if required. If the ulcer relapses further treatment courses may be given.
Prophylaxis of NSAID-induced peptic ulcer: 200 micrograms twice daily, three times daily or four times daily. Treatment can be continued as required. Dosage should be individualised according to the clinical condition of each patient.
Renal impairment: Available evidence indicates that no adjustment of dosage is necessary in patients with renal impairment.
Hepatic impairment: Mirolut is metabolised by fatty acid oxidising systems present in organs throughout the body. Its metabolism and plasma levels are therefore unlikely to be affected markedly in patients with hepatic impairment.
Elderly
The usual dosage may be used.
Paediatric population
Use of Mirolut in children has not yet been evaluated in the treatment of peptic ulceration or NSAID-induced peptic ulcer disease.
No special requirements.
